Adjuvant Capital

Adjuvant Capital is a venture capital firm focused on improving global health through investments in life science technologies that address high-burden public health challenges. They target historically overlooked market segments in emerging economies and low-income populations, seeking both social and financial returns for their investors. Their mission is to deploy capital in promising public health technologies and ensure their accessibility to those who need them most, focusing on areas like infectious diseases (HIV/AIDS, tuberculosis, malaria, tropical diseases, pandemic threats, AMR), maternal and child health, nutrition, and reproductive and sexual health. The firm primarily invests in technologies that have demonstrated safety and efficacy in humans, making preferred equity investments with the goal of accelerating the global availability of impactful medical innovations. Adjuvant's investment strategy is influenced by global trends like climate change, women's empowerment, urbanization, antimicrobial resistance, and globalization, guiding them toward emerging public health threats and high-impact solutions. Adjuvant Capital differentiates itself from traditional venture capital firms by focusing on underserved markets and aiming for a "double-bottom-line" return. They are backed by strategic investors and alternative asset managers who provide domain expertise and support. Healthcare spending in emerging economies and the drive for universal health equity create opportunities for significant growth in this sector, which Adjuvant seeks to capitalize on.

Infectious diseases (HIV/AIDS, tuberculosis, malaria, tropical diseases like schistosomiasis and onchocerciasis, pandemic threats such as MERS and Lassa fever, anti-microbial resistance (AMR)), maternal and child health, nutrition, reproductive and sexual health

Thematische Schwerpunkte und Zielmarktsegmente von Interesse.